WEBULL
WebtradeDownload

Progyny (PGNY) Following Its Earnings Beat And Lowered Outlook Has Fair Value Back In Focus

Simply Wall St · 3d ago

Progyny (PGNY) is back in focus after second quarter results topped revenue and non GAAP profit expectations, even as slightly lower full year guidance and a completed share buyback prompted a more cautious market reaction.

See our latest analysis for Progyny.

Recent trading shows that momentum in Progyny’s share price has cooled, with a 30 day share price return down 17.7% and a 7 day share price return down 5.6%, even though the 1 year total shareholder return is 10.5% and the 3 and 5 year total shareholder returns remain negative. The latest earnings beat, slightly lower full year guidance and completion of the share buyback help explain why the share price, now at US$26.28, reflects both interest in Progyny’s growth opportunities and a more cautious view on future risks.

If you are weighing Progyny’s latest move and want to see what else is gaining attention in healthcare, it is worth scanning 41 healthcare AI stocks.

With Progyny’s share price pulling back after an earnings beat and lower guidance, the question now is whether today’s valuation already reflects those risks or whether patience could offer a more attractive entry. Here is how the numbers stack up.

Most Popular Narrative: 22.3% Undervalued

Progyny's most followed valuation narrative pegs fair value at $33.82, which sits well above the latest close at $26.28. That gap rests on a detailed earnings and margin trajectory that analysts have mapped out for the next few years.

Investment in an integrated women's health platform (including new services such as pelvic floor therapy, leave navigation, and enhanced digital engagement) positions Progyny to cross sell adjacent products, resulting in higher share of wallet with current clients and additional revenue streams, supporting both topline and margin expansion.

Read the complete narrative.

Want the full story behind that $33.82 fair value for Progyny? The narrative leans on a specific growth path for revenue, earnings and profit margins that might surprise you.

Result: Fair Value of $33.82 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Progyny’s story can shift quickly if employers curb spending on premium fertility and women’s health benefits, or if regulatory changes restrict reproductive services.

Find out about the key risks to this Progyny narrative.

Next Steps

Given the mixed tone on Progyny so far, it makes sense to review the underlying data yourself and decide how compelling the risk reward trade off really looks. To see what investors are optimistic about right now, take a closer look at the 4 key rewards.

Looking for more investment ideas beyond Progyny?

If Progyny has your attention, do not stop here. Use the Simply Wall St screener to uncover other stocks that match the kind of opportunities you care about most.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.